Description
Lilotomab(TD-HY564016) is a research-grade recombinant antibody targetingCD37. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.